Skip Navigation


Carcinogenesis Advance Access originally published online on April 15, 2008
Carcinogenesis 2008 29(6):1124-1133; doi:10.1093/carcin/bgn093
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
29/6/1124    most recent
bgn093v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Jellicoe, M. M.
Right arrow Articles by Filipovska, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jellicoe, M. M.
Right arrow Articles by Filipovska, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Bioenergetic differences selectively sensitize tumorigenic liver progenitor cells to a new gold(I) compound

Matthew M. Jellicoe1,2, Scott J. Nichols1, Bernard A. Callus3, Murray V. Baker4, Peter J. Barnard4, Susan J. Berners-Price4, James Whelan5, George C. Yeoh1,2 and Aleksandra Filipovska1,2,*

1 Laboratory for Cancer Medicine, Western Australian Institute for Medical Research and Center for Medical Research, The University of Western Australia, Perth, Western Australia 6000, Australia
2 Biochemistry, School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia
3 Department of Biochemistry, La Trobe University, Victoria 3086, Australia
4 Chemistry, School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia
5 Australian Research Council Centre of Excellence in Plant Energy Biology, The University of Western Australia, Western Australia 6009, Australia

* To whom correspondence should be addressed. Tel: +61 8 9224 0330; Fax: +61 8 9224 0322; Email: afilipov{at}waimr.uwa.edu.au

A hallmark of cancer cells is their ability to evade apoptosis and mitochondria play a critical role in this process. Delineating mitochondrial differences between normal and cancer cells has proven challenging due to the lack of matched cell lines. Here, we compare two matched liver progenitor cell (LPC) lines, one non-tumorigenic [p53-immortalized liver (PIL) 4] and the other tumorigenic (PIL2). Analysis of these cell lines and a p53 wild-type non-tumorigenic cell line [bipotential murine oval liver (BMOL)] revealed an increase in expression of genes encoding the antiapoptotic proteins cellular inhibitor of apoptosis protein (cIAP) 1 and yes associate protein in the PIL2 cells, which resulted in an increase in the protein encoded by these genes. PIL2 cells have higher mitochondrial membrane potential ({Delta}{psi}m) compared with PIL4 and BMOL and had greater levels of reactive oxygen species, despite the fact that the mitochondrial antioxidant enzyme, manganese superoxide disumutase, was elevated at transcript and protein levels. Taken together, these results may account for the observed resistance of PIL2 cells to apoptotic stimuli compared with PIL4. We tested a new gold compound to show that hyperpolarized {Delta}{psi}m led to its increased accumulation in mitochondria of PIL2 cells. This compound selectively induces apoptosis in PIL2 cells but not in PIL4 or BMOL. The gold compound depolarized the {Delta}{psi}m, depleted the adenosine triphosphate pool and activated caspase-3 and caspase-9, suggesting that apoptosis was mediated via mitochondria. This investigation shows that the non-tumorigenic and tumorigenic LPCs are useful models to delineate the role of mitochondrial dysfunction in tumorigenesis and for the future development of mitochondria-targeted chemotherapeutics that selectively target tumor cells.

Abbreviations: ATP, adenosine triphosphate; BMOL, bipotential murine oval liver; cIAP, cellular inhibitor of apoptosis protein; DHE, dihydroethidium; DLC, delocalized lipophilic cation; HCC, hepatocellular carcinoma; [(iPr2Im)2Au]Cl, bis(1,3-di-isopropylimidazol-2-ylidene)gold(I) chloride; (iPr2Im)AuCl, 1,3-di-isopropylimidazol-2-ylidenegold(I) chloride; LPC, liver progenitor cell; MnSOD, manganese superoxide disumutase; {Delta}{psi}m, mitochondrial membrane potential; PIL, p53-immortalized liver; ROS, reactive oxygen species; TPMP, methyltriphenylphosphonium; Yap, yes-associated protein

Received February 20, 2008; revised March 20, 2008; accepted March 26, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.